This article was originally published in The Gray Sheet
Executive SummaryWill move its corporate ventures office from Minneapolis to Maastricht, The Netherlands before the end of the year, allowing Medtronic "to take advantage of a more favorable environment for medical innovation overseas," the company said. The office, headed by VP Michael Baker, directs development, regulatory affairs and pilot production for Medtronic's newest medical therapies, including projects in cardiomyoplasty, voiding/incontinence dysfunction and upper airway dysfunction. Just a "handful" of Medtronic's 10,000+ employees will make the move, the company said
You may also be interested in...
Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.